LabGenius

LabGenius

Synthetic biology company that uses AI, DNA synthesis, and robotics to discover biological molecules.

LabGenius is a privately held, synthetic biology company based in London, UK. It uses a combination of artificial intelligence, DNA synthesis, and robotics to discover high-value biological molecules.

The company's novel technology is able to produce trillions of variations of gene sequences, which can be used to create new biological materials using artificial intelligence. It can predict which gene mutations will improve a biological design, thereby enabling scientists to produce new therapeutics or other materials such as adhesives, catalysts, and sensors.

LabGenius, in partnership with leading multinationals, is developing various products, focusing on the areas of biotherapeutics, advanced materials, and personal care. In the biotherapeutics category, LabGenius' AI-driven evolution engine, EVA, is learning how to optimally enhance the stability of therapeutic proteins in protease rich environments such as the GI tract, tumor microenvironments, and inflammed tissues. The end goal is to enable the delivery of novel therapies for unmet clinical needs.

In the advanced materials area, engineered proteins can be used to form high value coatings, adhesives, fibres, catalysts, and sensors. LabGenius has completed several development projects in this area and are engaged in collaborative development with aerospace and defence companies.

Timeline

October 2019

LabGenius raises a $10,000,000 series A round from Air Street Capital, Obvious Ventures, iNovia Capital, Felicis Ventures, Lux Capital Management and Gigafund.

November 24, 2017

LabGenius raises $3.66m of investment

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
1 Result
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Dr. Adam Tomassi-Russel

Chief Commercial Officer

Dr. Annelie Oswald

Platform Scientist

Dr. Ben Mackrow

Synthetic Biologist

Dr. Chris Cozens

Molecular Biologist

Dr. Eyal Kazin

Data Scientist

Dr. Fiona Rowan

Biologics Scientist

Dr. Katya Putintseva

Data Scientist

Dr. Maria Bagniewska

Program Manager

Dr. Pedro Tizei

Automation Scientist

Dr. Pierre-Yves Colin

Molecular Biologist

Dr. Richard Menzies-Wilson

Operations Manager

Eddie Li

Full Stack Developer

George Morriss

Employee

Harry Rickerby

CSO

James Field

Founder & CEO

Leila Zegna

Investor Director

Mo Niknafs

Head of Non-Dilutive Financing

Oli Hall

Employee

Philipp Moehring

Investor

Staffan Piledahl

Software Engineer

Further reading

Title
Author
Link
Type
Date

LabGenius Locks Down $3.66m From Top-Tier Investors To Harness Evolution - SynBioBeta

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

LabGenius

James Field

London, England, United Kingdom

Machine learning for protein therapeutics

News

Title
Author
Date
Publisher
Description
Steve O'Hear
October 22, 2019
TechCrunch
LabGenius, a London-based startup applying AI and "robotic automation" to protein drug discovery, has raised $10 million in Series A funding. The round is led by Lux Capital and Obvious Ventures, with participation from Felicis Ventures, Inovia Capital, Air Street Capital and existing investors. Also investing is Recursion Pharmaceuticals' founder and CEO Chris Gibson, as [...]

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.